Narrative Update on CelLBxHealth
Analysts have maintained CelLBxHealth's target price at $0.11 per share, citing improved profit margin estimates and a slightly higher discount rate in their updated valuation model.
What's in the News
- Entered a non-exclusive collaboration and co-marketing agreement with QIAGEN Manchester Ltd., allowing the Parsortix platform to be offered in pharmaceutical projects that combine CTC enrichment and molecular analysis tools (Key Developments)
- Completed a follow-on equity offering totaling £6.8 million through the issuance of common stock (Key Developments)
- Filed additional follow-on equity offerings amounting to £1 million and £8.67 million to raise further capital (Key Developments)
- Special/Extraordinary Shareholders Meeting scheduled for December 15, 2025, in London (Key Developments)
- Changed company name from ANGLE plc to CelLBxHealth plc effective October 29, 2025 (Key Developments)
Valuation Changes
- Fair Value estimate remains stable at $0.105 per share, showing no change from previous assessments.
- The Discount Rate has risen slightly from 9.53% to 9.73%.
- Revenue Growth projections are unchanged at approximately 221.75%.
- The Net Profit Margin estimate has increased from 8.43% to 9.48%.
- The forecast for the future P/E ratio has fallen from 6.10x to 5.46x.
Have other thoughts on CelLBxHealth?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.